Hi Lisa–
    such a great question. I agree with Rajni. The oral targeted therapies are very challenging for many patients. There will definitely be a select group of patients in which these agents are used in the adjuvant setting, but the pyrexia and febrile syndrome make them quite challenging in more advanced melanoma patients.

    Latest Activity